In this issue:
Maintenance thalidomide +prednisone after autologous SCT in MM
Bortezomib retreatment in relapsed MM
Siltuximab in relapsed refractory MM
Novel agents and renal impairment reversibility in MM
FLC for identifying presymptomatic MM
2nd-line thalidomide and survival in MM
Autologous SCT for MM: identifying prognostic factors
HBV infection is associated with 8p deletion in MM
Weekly bortezomib in relapsed refractory MM
Allogeneic SCT with reducedintensity conditioning in MM
Please login below to download this issue (PDF)